MAGEA3 and neoplasm: First, although we analyzed immune responses against a pre-selected set of bona fide TAAs (NY-ESO-1, MAGE-A1, MAGE-A3, and p53), these do not represent the full range of tumor antigens expressed in ovarian cancer.